(Q35717799)

English

Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies

scientific article published on 11 October 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 August 2017

Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies (English)

1 reference

Europe PubMed Central

9 August 2017

Didier Bouscary

object named as

Didier Bouscary

9

0 references

object named as

Sylvie Chevret

19

0 references

20

object named as

Pierre Fenaux

1 reference

Europe PubMed Central

9 August 2017

author name string

Lionel Adès

1

1 reference

Europe PubMed Central

9 August 2017

Fabien Le Bras

2

1 reference

Europe PubMed Central

9 August 2017

Marie Sebert

3

1 reference

Europe PubMed Central

9 August 2017

Charikleia Kelaidi

4

1 reference

Europe PubMed Central

9 August 2017

Thierry Lamy

5

1 reference

Europe PubMed Central

9 August 2017

François Dreyfus

6

1 reference

Europe PubMed Central

9 August 2017

Virginie Eclache

7

1 reference

Europe PubMed Central

9 August 2017

Jacques Delaunay

8

1 reference

Europe PubMed Central

9 August 2017

Sorin Visanica

10

1 reference

Europe PubMed Central

9 August 2017

Pascal Turlure

11

1 reference

Europe PubMed Central

9 August 2017

Agnès Guerci Bresler

12

1 reference

Europe PubMed Central

9 August 2017

Marie-Paule Cabrol

13

1 reference

Europe PubMed Central

9 August 2017

Anne Banos

14

1 reference

Europe PubMed Central

9 August 2017

Michel Blanc

15

1 reference

Europe PubMed Central

9 August 2017

Norbert Vey

16

1 reference

Europe PubMed Central

9 August 2017

Alain Delmer

17

1 reference

Europe PubMed Central

9 August 2017

Eric Wattel

18

1 reference

Europe PubMed Central

9 August 2017

publication date

11 October 2011

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

97

1 reference

Europe PubMed Central

9 August 2017

2

1 reference

Europe PubMed Central

9 August 2017

213-218

1 reference

Europe PubMed Central

9 August 2017

Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269480

12 July 2018

Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269480

12 July 2018

A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269480

12 July 2018

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269480

12 July 2018

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269480

12 July 2018

A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Français des Myélodysplasies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269480

12 July 2018

Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269480

12 July 2018

5q-, twenty-five years later: a synopsis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269480

12 July 2018

International scoring system for evaluating prognosis in myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269480

12 July 2018

TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269480

25 September 2018

Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269480

25 September 2018

Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269480

25 September 2018

Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269480

25 September 2018

The 5q- syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269480

25 September 2018

Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269480

25 September 2018

New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/21993675

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3324/HAEMATOL.2011.045914

1 reference

https://api.fatcat.wiki/v0/release/r53ticguonhjtd4taxx557item

30 July 2022

based on heuristic

mapped directly with Wikidata item

release_r53ticguonhjtd4taxx557item

1 reference

https://api.fatcat.wiki/v0/release/r53ticguonhjtd4taxx557item

30 July 2022

based on heuristic

mapped directly with Wikidata item

1 reference

https://api.fatcat.wiki/v0/release/r53ticguonhjtd4taxx557item

30 July 2022

based on heuristic

mapped directly with Wikidata item

1 reference

https://api.fatcat.wiki/v0/release/r53ticguonhjtd4taxx557item

30 July 2022

based on heuristic

mapped directly with Wikidata item

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35717799&oldid=1801332938"